Oura Prices IPO at Up to $15.6 Billion Valuation, Betting on AI-Driven Preventive Health

Oura wants public market investors to pay up front for a story that has, so far, mostly played out in private funding rounds. The smart ring maker is offering 50 million shares priced between $40 and $44, targeting a $2.2 billion raise. At the top of that range, the company's fully diluted valuation reaches $15.62 billion, according to a Reuters calculation. That figure represents a substantial markup from the $11 billion valuation Oura secured in its $900 million Series E round last October.

The offering itself is split. Oura is selling 13.5 million shares directly, while existing stockholders are offloading 36.5 million. That structure matters. The bulk of proceeds will flow to early backers and insiders rather than the company's own balance sheet, a common pattern in late-stage tech IPOs but one worth flagging for investors weighing dilution against growth capital.

The company will list on the Nasdaq under the ticker "OURA." Founded in Finland in 2013, it has raised more than $1.5 billion to date across private rounds before this offering.

The Growth Numbers Behind the Pitch

Oura's S-1 filing lays out a business that has scaled quickly. Revenue grew from $698 million in the nine months ended June 30, 2025, to $1.2 billion in the same period a year later, a 74% year-over-year increase. Hardware sales brought in $974 million of that 2026 total, with membership revenue contributing $240 million, up from $589 million and $109 million respectively in the prior period. Trailing twelve-month revenue now exceeds $1.4 billion.

Profitability is real, if modest relative to revenue. Gross margins sat at 55% for the nine-month period, with net income of $61 million and adjusted EBITDA of $107 million. That's a meaningfully healthier profile than many consumer hardware companies show at this stage of a growth cycle.

Membership economics look strong on paper. Oura counts 5 million paid members and expects to end fiscal 2026 with roughly 5.7 million, representing 96% year-over-year growth. More than 94% of ring activations have historically converted to paid membership, with roughly 85% retention over 12 months. Members wear the device about 23 hours a day. That usage pattern has produced nearly 42 billion hours of longitudinal biometric data, which the company positions as a defensible moat.

Oura frames itself less as a hardware company and more as a data and software platform with a recurring revenue engine attached. Hardware sales, the company says, cover customer acquisition costs upfront, while memberships generate the long-term margin. It's a model investors have seen before in razor-and-blade businesses, though the health data angle adds both opportunity and regulatory complexity.

The company estimates its serviceable market at more than $90 billion as healthcare spending shifts toward proactive and personalized care. Currently, Oura accounts for approximately 2% of annual global wearable shipments. Management argues it is simultaneously expanding the category and taking share: 33% of new members report Oura as their first wearable, while 29% say they replaced an existing wearable and 37% wear Oura alongside another device.

Demographic data in the filing also points to a broader addressable base than typical fitness trackers reach. Female members and male members have each grown at compound annual growth rates exceeding 90% since fiscal 2024. Roughly 72% of members are women, 27% are over age 45, and 37% report household income below $100,000. More than half of members report managing at least one chronic condition, a data point Oura uses to argue it is penetrating populations that wearables have historically struggled to engage.

Healthcare partnerships add another layer to the pitch. Oura has agreements with Cigna to offer its ring as a health plan benefit, and with Essence Healthcare, which provides the device at no cost to some Medicare Advantage members. Roughly a third of Essence's members have opted in, and that partnership has expanded into clinical programs including sleep apnea risk identification. The company also cites integrations with Natural Cycles, Dexcom, Strava, Lumeris and Maven Clinic across more than 1,200 partners, supported by an API-first architecture and more than 1,140 patents and patent applications.

International expansion remains an underdeveloped lever. Only 20% of hardware sales currently come from outside the U.S., leaving substantial runway if Oura can replicate its domestic playbook abroad.

Investment Implications

Valuing Oura requires weighing genuine operating momentum against a rich multiple. A 74% revenue growth rate paired with positive net income and adjusted EBITDA is not the profile of a typical unprofitable consumer hardware IPO candidate. That combination should support investor demand, and the underwriting syndicate reflects that confidence: Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen & Company and Jefferies are leading the offering, backed by BofA Securities, Barclays and Wells Fargo among others.

The key risk is durability of the growth rate and the multiple investors are being asked to pay for it. At $15.62 billion, Oura would trade at roughly 11 times trailing twelve-month revenue of $1.4 billion. That's a premium valuation that assumes continued membership growth near triple-digit rates, expanding healthcare partnerships, and successful international scaling, none of which is guaranteed to persist at current pace.

Watch retention trends and hardware-to-membership conversion rates in coming quarters as the clearest signals of whether the flywheel Oura describes is actually compounding or merely a snapshot of a favorable growth phase. Also worth monitoring: how much of future revenue growth comes from healthcare payer partnerships versus direct consumer sales, since payer relationships could offer more durable, less discretionary revenue streams than consumer wellness spending, which tends to be cyclical. For investors comfortable paying a premium for a profitable, fast-growing wearables company with a plausible healthcare data moat, Oura's IPO merits a look. For those wary of rich multiples on unproven long-term market assumptions, patience through the first few quarters as a public company seems the more prudent course.